IQVIA Holdings Inc. (NYSE:IQV) Receives $259.13 Consensus PT from Brokerages

IQVIA Holdings Inc. (NYSE:IQV) has been assigned an average rating of “Moderate Buy” from the nineteen brokerages that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $259.13.

Several brokerages have recently issued reports on IQV. Argus raised shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Robert W. Baird dropped their price objective on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. StockNews.com lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th.

IQVIA Stock Performance

IQVIA stock opened at $202.94 on Tuesday. IQVIA has a 1 year low of $200.20 and a 1 year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market cap of $36.83 billion, a PE ratio of 26.63, a PEG ratio of 2.20 and a beta of 1.51. The company’s 50-day moving average is $228.86 and its two-hundred day moving average is $228.77.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several large investors have recently added to or reduced their stakes in the business. Canada Pension Plan Investment Board increased its stake in IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Lazard Asset Management LLC raised its position in IQVIA by 0.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock valued at $825,416,000 after purchasing an additional 30,014 shares during the last quarter. Farallon Capital Management LLC lifted its stake in IQVIA by 3.1% in the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after acquiring an additional 86,870 shares during the period. FMR LLC boosted its stake in shares of IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of IQVIA by 3.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company’s stock worth $634,927,000 after acquiring an additional 92,293 shares during the period. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.